General Hospital of Rhodes

Recent papers from General Hospital of Rhodes

1. Temporal patterns of tuberculosis-associated hyperglycaemia and its effect on treatment outcomes in individuals not previously diabetic: A prospective cohort studyPLoS ONE · 2026
2. Real‐World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease—A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases ( IG ‐ IBD )Alimentary Pharmacology & Therapeutics · 2026
3. Exploring the potential benefits of allergen immunotherapy beyond respiratory allergyExpert Opinion on Biological Therapy · 2026
4. Local impedance tissue characterization to enhance accessory pathway ablationEP Europace · 2026
5. A New Catalogue of Historical Eruptions in Santorini Volcano: Documentation and Completeness AnalysisGeoHazards · 2026
6. Real-world data on CLDN18.2 expression in gastric and gastroesophageal cancer patients.Journal of Clinical Oncology · 2026
7. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical TreatmentJournal of Crohn s and Colitis · 2026
8. Vaccination in Oncology Patients: Evidence, Clinical Challenges, and Future DirectionsVaccines · 2026
9. Erratum in: Exploring the administrative burden faced by hematologists: a comprehensive study in ItalyGlobal & Regional Health Technology Assessment · 2026
10. Behind the seizures: Exploring the emotional burden of adolescents with idiopathic generalized epilepsyEpilepsy & Behavior · 2026
11. Multicenter Real-World Outcomes of Risankizumab in Crohn’s Disease: The RESOLVE IG-IBD StudyThe American Journal of Gastroenterology · 2026
12. Abstract PS3-09-14: Caught in the Middle: Discrepancies Between Immunohistochemistry and Oncotype DX in Hormone Receptor Assessment Leading to Triple Negative Reclassification—Tumour Heterogeneity or Just Low ER Expression?Clinical Cancer Research · 2026
13. Abstract PS3-08-24: Association of Oncotype DX Recurrence Score with Germline Mutations in Cancer Susceptibility Genes Including BRCA1/2 in HR+/HER2− Early Breast CancerClinical Cancer Research · 2026
14. Abstract PS3-05-05: High-risk cancer susceptibility genes mutation carriers’ compliance with surgical risk reduction for breast and ovarian cancerClinical Cancer Research · 2026
15. Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitisClinical Gastroenterology and Hepatology · 2026
16. P0308Application and validation of Milan Ultrasound Criteria in a large cohort of 181 patients with Ulcerative Colitis: a multicenter real world Italian studyJournal of Crohn s and Colitis · 2026
17. P0598MIRACLE-UC: Mirikizumab Investigation of Real-world Assessment of Clinical and Long-term Effectiveness and Adverse Events in Patients with Ulcerative Colitis - A Multicenter Prospective Study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).Journal of Crohn s and Colitis · 2026
18. DOP035Upadacitinib: Personalized Goals for Remission and Disease Evaluation in Patients with Crohn’s Disease (UPGRADE-CD) - A Multicenter Prospective Study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).Journal of Crohn s and Colitis · 2026
19. P0706Effectiveness and safety of switching from a first JAKi to a subsequent JAKi in patients with ulcerative colitis: preliminary retrospective data from IG-IBD multicentre cohort studyJournal of Crohn s and Colitis · 2026
20. P0248Transperineal ultrasound vs MRI in the assessment of Perianal Crohn’s Disease: A comparative study using a validated scoring systemJournal of Crohn s and Colitis · 2026